High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis
Open Access
- 24 January 2017
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (2) , e1265719
Abstract
Bacillus Calmette–Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) can significantly reduce the risk of recurrence and progression. However, BCG therapy may fail in up to a half of treated patients and may also cause toxicities. Biomarkers to predict the effectiveness of BCG therapy are desired to pre-select patients for BCG therapy to maximize efficacy while avoid unnecessary toxicity. Twelve cytokines were measured in 100 blood and 112 urine samples using cytokine antibody array and correlated with recurrence-free survival in overall and BCG-treated NMIBC patients. Of the 12 cytokines, interleukin (IL) -2, IL-8, IL-10, tumor necrosis factor (TNF)-α, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)-γ were measurable in more than 30% of peripheral blood leukocyte (PBL) samples. Only IL-8 in PBL was found to be significantly associated with tumor recurrence, especially in those who receiving BCG therapy (hazard ratio [HR] = 4.24; 95% confidence interval [95%CI] = 1.65–10.88; p = 0.003). The median recurrence-free survival time for BCG-treated patients with high baseline IL-8 levels were much shorter than those with low IL-8 levels (7.9 vs. >78.4 mo, p = 0.004). Furthermore, consistent associations between urinary IL-8 levels and tumor recurrence in patients receiving BCG therapy were observed in 58 pre-BCG and 54 long-term post-BCG-treated urine samples (both p ≤ 0.005). High urinary baseline IL-8 level also predicted shorter time to tumor recurrence in NMIBC patients (both p ≤ 0.004). By using antibody array-based technology in two separate cohorts of NMIBC patients, we found that PBL and urinary baseline IL-8 levels were significantly associated with tumor recurrence after BCG therapy.Keywords
This publication has 37 references indexed in Scilit:
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013European Urology, 2013
- Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder CancerBMC Urology, 2012
- IL-8 as a urinary biomarker for the detection of bladder cancerBMC Urology, 2012
- Targeting IL-8 in colorectal cancerExpert Opinion on Therapeutic Targets, 2012
- Helper T-cell differentiation and plasticity: insights from epigeneticsImmunology, 2011
- EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 UpdateEuropean Urology, 2011
- Urinary Interleukin-8 Predicts the Response of Standard and Low Dose Intravesical Bacillus Calmette-Guerin (Modified Danish 1331 Strain) for Superficial Bladder CancerJournal of Urology, 2002
- URINARY INTERLEUKIN-8/CREATININE LEVEL AS A PREDICTOR OF RESPONSE TO INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY IN BLADDER TUMOR PATIENTSJournal of Urology, 1997
- Intravesical Versus Intravesical Plus Intradermal Bacillus Calmette-Guerin: A Prospective Randomized Study In Patient With Recurrent Superficial Bladder TumorsJournal of Urology, 1996
- Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components.Journal of Clinical Investigation, 1995